Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in BRICS has been experiencing significant growth in recent years.
Customer preferences: One of the primary reasons for the growth of the Oncology Drugs market in BRICS is the increasing demand for cancer treatment. With the rising incidence of cancer in these countries, patients are seeking effective treatment options that can improve their chances of survival. Additionally, the increasing awareness about the benefits of early detection and treatment is driving more people to seek medical attention for cancer.
Trends in the market: Brazil is the largest market for Oncology Drugs in the BRICS region. The country has a well-established healthcare system that provides access to advanced cancer treatments. The Oncology Drugs market in Brazil is expected to grow at a steady pace due to the increasing incidence of cancer and the growing demand for targeted therapies.Russia is another important market for Oncology Drugs in the BRICS region. The country has a high incidence of cancer, particularly lung cancer, which is driving the demand for innovative cancer treatments. The Oncology Drugs market in Russia is expected to grow rapidly due to the increasing availability of advanced cancer treatments and the growing number of cancer patients.India is also an important market for Oncology Drugs in the BRICS region. The country has a large population and a high incidence of cancer, particularly breast and lung cancer. The Oncology Drugs market in India is expected to grow rapidly due to the increasing demand for targeted therapies and the growing number of cancer patients.China is the largest market for Oncology Drugs in the world. The country has a large population and a high incidence of cancer, particularly lung and liver cancer. The Oncology Drugs market in China is expected to grow rapidly due to the increasing demand for innovative cancer treatments and the growing number of cancer patients.
Local special circumstances: In Brazil, the government has implemented several initiatives to improve access to cancer treatment, including the provision of free cancer drugs and the establishment of cancer treatment centers. This has helped to increase the demand for Oncology Drugs in the country.In Russia, the government has also implemented several initiatives to improve access to cancer treatment, including the provision of free cancer drugs and the establishment of cancer treatment centers. However, the country still faces challenges in terms of access to advanced cancer treatments, particularly in rural areas.In India, the government has implemented several initiatives to improve access to cancer treatment, including the provision of free cancer drugs and the establishment of cancer treatment centers. However, the country still faces challenges in terms of access to advanced cancer treatments, particularly in rural areas.In China, the government has implemented several initiatives to improve access to cancer treatment, including the provision of free cancer drugs and the establishment of cancer treatment centers. However, the country still faces challenges in terms of access to advanced cancer treatments, particularly in rural areas.
Underlying macroeconomic factors: The growth of the Oncology Drugs market in BRICS is also driven by several macroeconomic factors, including the increasing healthcare expenditure, the rising disposable income, and the growing aging population. As these countries continue to develop and their economies grow, the demand for Oncology Drugs is expected to increase further.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
